GBA's "2021 Stock Phantasma"

Discussion in 'Stocks' started by stonedinvestor, Jan 1, 2021.

  1. You could serve tea on that belly
     
    #481     Jan 15, 2021
  2. janes

    janes

    about PLTR, they're saying it's because ARK bought a lot of stock last night and maybe today.
     
    #482     Jan 15, 2021
  3. 4:23 mark we aim to be the alcohol for Purell and all the other disinfectant brands for the west coast....

     
    #483     Jan 15, 2021
  4. Yikes I see where this is all going-- It's Bladrunner... it's happening.

     
    #484     Jan 15, 2021
  5. Who is Ark? Investment fund?

    Van's Vietnam.
     
    #485     Jan 15, 2021
  6. Wait I'm confused $27.50 or $25.50.??

    I left the city I wrote down $27.50-PLTR What up? And now it's $25.50.
     
    #486     Jan 15, 2021
  7. This name came up before memory memory..

    How frustrating!

    Collegium Pharmaceutical, Inc. (COLL)
    24.08+1.79 (+8.03%)<--- why is this on my watch list???
    As of 3:57PM EST. Market open.
     
    #487     Jan 15, 2021
  8. janes

    janes

    it dropped again (PLTR). I've been trading this one for a few weeks--buying at around 24 and selling at 26ish. i'm working on the assumption it won't really start going up until the earnings report and stock release. but who knows i guess.
     
    Last edited: Jan 15, 2021
    #488     Jan 15, 2021
    vanzandt likes this.
  9. --
    Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 12/29 COLL, RVNC Needham analyst Serge Belanger named Collegium Pharmaceutical (COLL) as his 2021 best idea and added the company to Needham Conviction List in place of Revance Therapeutics (RVNC), which was removed. The analyst is also keeping his Buy rating and $34 price target on Collegium.
     
    #489     Jan 15, 2021
  10. and then this Monday--

    Collegium Pharmaceutical price target raised to $33 from $29 at H.C. Wainwright 06:29 COLL H.C. Wainwright analyst Oren Livnat raised the firm's price target on Collegium Pharmaceutical to $33 from $29 and reiterates a Buy rating on the shares.
     
    #490     Jan 15, 2021